Deals cover identification, validation, assay development, HTS, and lead optimizations.

Axxam signed two drug research collaboration agreements with Boehringer Ingelheim. The first collaboration agreement aims to identify and validate therapeutic targets with subsequent assay development, high-throughput screening (HTS), and lead optimizations.

The second agreement covers the transfer of protein material and a corresponding specific functional assay for HTS to Boehringer Ingelheim.

Axxam will receive fees as the collaboration progresses and milestone payments for successful exploitation of results through development stages.

Previous articleOGT and Sanger Institute Work on a Test for Prenatal Syndromes
Next articleTargacept Expands Office and Lab Space